Clinical Edge Journal Scan

Joint tenderness at 3 months post-diagnosis predicts long-term pain in early RA


 

Key clinical point: A substantial proportion of patients with early rheumatoid arthritis (RA) had unacceptably high levels of pain with or without low inflammation at 2 years after diagnosis, with joint tenderness at the 3-month follow-up predicting long-term pain despite low inflammation.

Major finding: Nearly one third of patients with early RA had unacceptable pain levels after 2 years of follow-up, with almost 80% of them also having low inflammation. At the 3-month follow-up, the difference between tender and swollen joint counts predicted the 2-year risk for unacceptable pain (odds ratio [OR] 2.00; P < .05) and unacceptable pain with low inflammation (OR 2.02; P < .05).

Study details: Findings are from a retrospective study including 275 patients with early RA.

Disclosures: This study was supported by The Swedish Research Council, The Swedish Rheumatism Association, and Lund University. Some authors declared working as a medical solution lead in rheumatology or receiving consulting fees, speaking fees, and unrestricted grant from various sources. Three authors declared no conflicts of interest.

Source: Eberhard A et al. Joint tenderness at 3 months follow-up better predicts long-term pain than baseline characteristics in early rheumatoid arthritis patients. Rheumatology (Oxford). 2023 (Jun 14). Doi: 10.1093/rheumatology/kead278

Recommended Reading

Progressing joint damage: An indication to consider intensive treatment in RA patients in remission or LDA
MDedge Rheumatology
Sarcopenia prevalence and risk in older RA patients
MDedge Rheumatology
Methotrexate does not impair sperm quality, small study finds
MDedge Rheumatology
Commentary: DMARD and HCQ in RA, July 2023
MDedge Rheumatology
Does colchicine have a role in treating excess ASCVD risk in patients with chronic inflammatory conditions?
MDedge Rheumatology
Antidrug antibody effects compared across RA biologics
MDedge Rheumatology
Humira biosimilars: Five things to know
MDedge Rheumatology
Tofacitinib shows marginal edge over adalimumab in real-world patients with RA
MDedge Rheumatology
Certolizumab pegol and abatacept show superiority over conventional therapy in early RA
MDedge Rheumatology
Joint involvement starts earlier and more severely in hands than in feet in RA
MDedge Rheumatology